• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

缬沙坦对肝纤维化大鼠瘦素、瘦素受体及Ⅰ型胶原表达的影响

Effect of valsartan on the expression of leptin, leptin receptor and collagen in rats with hepatic fibrosis

摘要:

目的 探讨血管紧张素Ⅱ1型受体拮抗剂缬沙坦对肝纤维化大鼠瘦素、瘦素受体及胶原表达的影响. 方法 36只Wistar雄性大鼠随机分为对照组、模型组、药物组,每组12只,四氯化碳背部皮下注射法造肝纤维化模型,药物组于造模开始缬沙坦灌胃,8周末处死.肝组织HE和Masson染色观察肝纤维化程度.酶联免疫吸附法测定血清瘦素(LP)、转化生长因子β 1(TGFβ 1)浓度,逆转录PCR检测肝组织LP mRNA、瘦素受体(OB-R) mRNA水平,Western blot检测肝脏LP、OB-R、Ⅰ型胶原(collagen Ⅰ)蛋白表达.多组间数据采用单因素方差分析,血清LP与TGFβ1行线性相关分析.结果 缬沙坦干预后肝组织HE和Masson染色显示纤维化程度明显减轻.对照组大鼠血清LP、TGFβ1水平分别为(18.92±7.10) ng/ml、(9.13±1.58) pg/ml,与模型组的(46.92±28.54) ng/ml、(16.39土3.56)pg/ml,及药物组的(29.27土7.27)nng/ml、(12.24±2.94)pg/ml比较,F值分别为7.864和20.057,P值均<0.05,差异均有统计学意义.对照组肝脏LP、OB-R mRNA相对表达量分别为0.35±0.18、0.62±0.18,与模型组的1.79±1.79、1.52土1.44,及药物组的0.48±0.34、0.75土0.26比较,F值分别为6.914、3.894,P值均<0.05,差异均有统计学意义.肝脏LP、OB-R、collagen Ⅰ蛋白相对表达量:对照组分别为0.71±0.13、0.81±0.11、0.76±0.13,模型组分别为0.97土0.06、1.04±0.06、1.05±0.04,药物组分别为0.74±0.05、0.93士0.05、0.91±0.05,三组比较,F值分别为15.425、13.757、19.130,p值均<0.001,差异均有统计学意义. 结论 血管紧张素Ⅱ1型受体拮抗剂缬沙坦可降低肝纤维化大鼠瘦素、瘦素受体的表达,减少TGFβ1、collagen Ⅰ的产生,发挥抗肝纤维化的作用.

更多
abstracts:

Objective To investigate the effects ofangiotensin Ⅱ type 1 receptor antagonist valsartan on leptin,leptin receptor and collagen in rats with hepatic fibrosis.Methods Thirty-six male wistar rats were randomly divided into control group,model group and drug-treated group,with 12 rats in each group.Liver fibrosis models were made by subcutaneous injection of carbon tetrachloride on the dorsal of the rats,simultaneously gastric gavage with Valsartan and were killed at the end of 8th week.The degree of liver fibrosis was observed by HE and Masson staining.The serum leptin (LP) and TGFβ1 were determined by ELISA.Liver LP mRNA and leptin receptor mRNA (OB-R mRNA) were detected by RT-PCR.Liver LP,OB-R and collagen Ⅰ were detected by Western blot.The data of multiple groups were analyzed by one-way analysis variance (ANOVA),and linear correlation was performed between serum LP and TGF β1.Results After the intervention of valsartan,HE and Masson staining showed that the degree of liver fibrosis was significantly reduced.The levels of serum LP and TGFβ1 in the control group were (18.92 ± 7.10) ng/ml and (9.13 ± 1.58)pg/ml respectively,which were significantly lower than those in the model group (46.92 ± 28.54) ng/ml and (16.39 ± 3.56) pg/ml,And (29.27 ± 7.27) ng/ml and (12.24 ± 2.94) pg/ml in the drug-treated group,respectively.The F values were 7.864 and 20.057 respectively.The P values were < 0.05.The differences were statistically significant.The relative expression levels of LP and OB-R mRNA in the control group were 0.35 ± 0.18 and 0.62 ±0.18,respectively,which were significantly lower than those in the model group (1.79 ± 1.79 and 1.52 ± 1.44,and drag-treated group 0.48 ± 0.34 and 0.75 ± 0.26,respectively),F values =6.914,3.894,P values were < 0.05,the differences were statistically significant.The relative expression levels of LP,OB-R and collaten Ⅰ in liver were 0.71 ± 0.13,0.81 ± 0.11 and 0.76 ± 0.13 in the model group,0.97 ± 0.06,1.04 ± 0.06,and 1.05 ±0.04 respectively in the drug-treated group and 0.74 ± 0.05,0.93 ± 0.05 and 0.91 ± 0.05.The F values were 15.425,13.757 and 19.130 respectively in three groups (P < 0.001),the difference was statistically significant.Conclusion Valsartan,an angiotensin Ⅱ type 1 receptor antagonist,can reduce the expression of leptin and leptin receptor,reduce the production of TGFβ1 and collaten Ⅰ,and play an anti-hepatic fibrosis effect.

More
作者: 黄会芳 [1] 霍新梅 [1] 霍丽娟 [1] 申凤俊 [1] 吴龙龙 [1]
期刊: 《中华肝脏病杂志》2018年26卷2期 119-124页 MEDLINEISTICPKUCSCD
栏目名称: 肝纤维化·肝硬化
DOI: 10.3760/cma.j.issn.1007-3418.2018.02.009
发布时间: 2018-04-04
基金项目:
山西省自然科学基金项目(2014011044-4)Shanxi Provincial Natural Science Foundation of China
  • 浏览:377
  • 下载:333

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷